Patients in the POUT trial were randomized to either a platinum-based adjuvant chemotherapy arm or a surveillance arm. Data from 458 patients who underwent RC between October 2005 and October 2020 and 146 in the PURE-01 trial was analyzed. Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity. The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted. The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered. The impact of squamous and other histologies on outcomes with EV are dissected. The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored. With a high response rate and manageable toxicity, further research into the use of SG in patients with mUC is warranted. The guidelines included recommendations for treatment with TURBT and postoperative intravesical chemotherapy. The quality of patient-reported outcome analyses over the past 15 years is unknown, as reporting has waned. Researchers investigated the ability of variant histology to predict oncological outcomes. Dr. Tawagi provides her thoughts on treatment selection and sequencing for mUC, especially after progression on EV/pembro. The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment. The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options. The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial. The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma. The panel weighed in on treatment selection after patient progression on EV/pembrolizumab. The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab. The panel discussed how enfortumab vedotin and pembrolizumab figures to change the bladder cancer treatment landscape. Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.